Kunming Longjin Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Kunming Longjin Pharmaceutical's earnings have been declining at an average annual rate of -43.6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 22.4% per year.
Belangrijke informatie
-43.6%
Groei van de winst
-43.6%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | -22.4% |
| Rendement op eigen vermogen | -12.2% |
| Nettomarge | -86.3% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
What Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) 38% Share Price Gain Is Not Telling You
Aug 14
Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) May Have Run Too Fast Too Soon With Recent 40% Price Plummet
Jun 30Risks Still Elevated At These Prices As Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) Shares Dive 26%
Apr 26We're Not Very Worried About Kunming Longjin Pharmaceutical's (SZSE:002750) Cash Burn Rate
Apr 17Revenues Not Telling The Story For Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) After Shares Rise 29%
Mar 08Opbrengsten en kosten
Hoe Kunming Longjin Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 62 | -54 | 70 | 15 |
| 30 Jun 24 | 82 | -59 | 90 | 19 |
| 31 Mar 24 | 91 | -67 | 98 | 20 |
| 31 Dec 23 | 87 | -71 | 95 | 22 |
| 30 Sep 23 | 91 | -79 | 98 | 23 |
| 30 Jun 23 | 88 | -69 | 92 | 23 |
| 31 Mar 23 | 97 | -65 | 98 | 25 |
| 01 Jan 23 | 123 | -56 | 110 | 25 |
| 30 Sep 22 | 211 | -7 | 133 | 23 |
| 30 Jun 22 | 383 | -4 | 162 | 23 |
| 31 Mar 22 | 544 | 1 | 191 | 18 |
| 01 Jan 22 | 703 | 3 | 208 | 20 |
| 30 Sep 21 | 683 | 16 | 211 | 15 |
| 30 Jun 21 | 551 | 18 | 210 | 18 |
| 31 Mar 21 | 419 | 19 | 200 | 19 |
| 31 Dec 20 | 254 | 12 | 186 | 20 |
| 30 Sep 20 | 251 | -22 | 186 | 23 |
| 30 Jun 20 | 245 | -26 | 184 | 20 |
| 31 Mar 20 | 251 | -33 | 194 | 23 |
| 31 Dec 19 | 275 | -23 | 209 | 21 |
| 30 Sep 19 | 273 | 1 | 222 | 24 |
| 30 Jun 19 | 299 | 4 | 241 | 29 |
| 31 Mar 19 | 318 | 12 | 251 | 33 |
| 31 Dec 18 | 336 | 14 | 267 | 32 |
| 30 Sep 18 | 341 | 19 | 272 | 28 |
| 30 Jun 18 | 339 | 23 | 253 | 41 |
| 31 Mar 18 | 328 | 28 | 240 | 29 |
| 31 Dec 17 | 304 | 35 | 211 | 27 |
| 30 Sep 17 | 287 | 48 | 185 | 22 |
| 30 Jun 17 | 262 | 81 | 169 | 0 |
| 31 Mar 17 | 238 | 89 | 131 | 0 |
| 31 Dec 16 | 224 | 91 | 108 | 0 |
| 30 Sep 16 | 196 | 91 | 80 | 0 |
| 30 Jun 16 | 182 | 67 | 58 | 0 |
| 31 Mar 16 | 179 | 63 | 55 | 0 |
| 31 Dec 15 | 181 | 62 | 53 | 0 |
| 30 Sep 15 | 194 | 64 | 50 | 0 |
| 30 Jun 15 | 194 | 66 | 51 | 0 |
| 31 Mar 15 | 195 | 67 | 53 | 0 |
| 31 Dec 14 | 187 | 64 | 51 | 0 |
| 31 Dec 13 | 179 | 75 | 44 | 0 |
Kwaliteitswinsten: 002750 is currently unprofitable.
Groeiende winstmarge: 002750 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 002750 is unprofitable, and losses have increased over the past 5 years at a rate of 43.6% per year.
Versnelling van de groei: Unable to compare 002750's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 002750 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 002750 has a negative Return on Equity (-12.19%), as it is currently unprofitable.